Rapid Protein Access for Drug Discovery Through a Semiconductor-based Technology
ABSTRACT
Nuclera is driven by the mission to better human health by increasing accessibility to proteins. We are committed to providing rapid access to high-quality, soluble, active proteins at the benchtop allowing researchers to accelerate their protein projects, enabling faster success.
Using Nuclera’s eProtein Discovery™ system scientists can automate construct screening to inform off-platform protein scale up, delivering reliable protein in-hand (µg-mg amounts) in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system.
Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
BIOGRAPHY
Michael Chen is the co-founder and CEO of Nuclera, a Cambridge UK and Boston US based life science tools company revolutionizing protein accessibility through the eProtein Discovery rapid protein access benchtop platform. With a mission to improve human health, Michael and his classmates founded Nuclera in response to the costly barriers to protein access for research and drug discovery. As CEO, he drives core inventions, sets the company's vision and strategy, and oversees its growth across two continents with over 100 employees.
Before Nuclera, Michael conducted scientific research for ten years, specializing in nucleic acid chemistry, protein expression, and crystallography. His work has resulted in twelve published papers, including a publication in Nature. Michael holds a BSc in Chemistry from the Georgia Institute of Technology and a PhD in Structural Biology/Chemistry from the University of Cambridge and the National Institutes of Health.